IBJNews

Lilly shares rise after drugmaker reports solid second quarter

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co. shares jumped 2.6 percent Wednesday morning after the drug maker reported better-than-expect results for the second quarter.

Strong sales and penny-pinching helped Lilly beat Wall Street’s expectations in the quarter, leading the company to raise its profit forecast for the year.

The Indianapolis-based drugmaker reported earnings of $1.2 billion in the three months ended June 30, an increase of 31 percent compared with same quarter last year. Earnings per share totaled $1.11, compared with 83 cents a year ago.

Excluding a restructuring charge of $63.5 million from the closing of a plant in Germany, Lilly would have earned $1.16 per share. On that basis, analysts were expecting earnings of $1 per share, according to a survey by Thomson Financial.

Because it outperformed those expectations, Lilly hiked up its profit expectations for the year by a range of 13 cent to 18 cents per share. The company now expects to earn between $4.28 and $4.38 for the year.

In the second quarter, Lilly was able to boost its sales 6 percent worldwide to $5.9 billion. Analysts were expecting revenue of $5.82 billion.

"Continued operating and financial discipline, along with a maturing pipeline of potential new medicines, gives me great confidence in the company's ability to meet the challenges we face from upcoming patent expirations and to resume growth after 2014,” Lilly CEO John Lechleiter said in a prepared statement.

Lechleiter took a leave of absence on May 13 to have surgery on a dilated aoarta. He returned on July 8.

 “It looks like they were doing some pretty good work while I was gone,” Lechleiter said.

Lilly’s bestselling drug, the antidepressant Cymbalta, is set to lose its U.S. patent protection in December, after which its sales will switch to cheaper generics. Sales of Cymbalta grew 22 percent in the second quarter, to nearly $1.5 billion.

Lilly already lost patent protection on its former bestseller, the antipsychotic Zyprexa, in late 2011. And Lilly also will lose patent protection on Evista, an osteoporosis drug, next year. Lilly is hoping to win approval on new diabetes and cancer drugs to offset those coming hits to its sales.

The company has cut costs to help fund its drive for new drugs, and last week said it would freeze wages for most of its workers.

“Management appears to be showing prudent cost discipline in anticipation of the Cymbalta patent cliff,” Mark Schoenebaum, an analyst with International Strategy & Investment Group in New York said in a report. “Smart expense control should increase the street’s confidence that Lilly is serious about dramatically improving operating margins post-2014.”

Lilly expects a 20-percent reduction in revenue in 2014 because of the U.S. expiration of the Cymbalta and Evista patents, a company spokesman said July 17. Lilly had hoped to avoid more cost cuts in the medium term, Lechleiter said.

“We’re losing a lot of revenue when at the same time we’ve got to launch our phase III products,” he said.

“You don’t take these actions lightly. This is the second such announcement in three years,” Lechleiter said of the wage freeze.
 

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. I would not vote for Bayh if he did run. I also wouldn't vote for Pence. My guess is that Bayh does not have the stomach to oppose persons on the far left or far right. Also, outside of capitalizing on his time as U. S. Senator (and his wife's time as a board member to several companies) I don't know if he is willing to fight for anything. If people who claim to be in the middle walk away from fights with the right and left wing, what are we left with? Extremes. It's probably best for Bayh if he does not have the stomach for the fight but the result is no middle ground.

  2. JK - I meant that the results don't ring true. I also questioned the 10-year-old study because so much in the "health care system" has changed since the study was made. Moreover, it was hard to get to any overall conclusion or observation with the article. But....don't be defensive given my comments; I still think you do the best job of any journalist in the area shedding light and insight on important health care issues.

  3. Probably a good idea he doesn't run. I for one do not want someone who lives in VIRGINIA to be the governor. He gave it some thought, but he likes Virginia too much. What a name I cannot say on this site! The way these people think and operate amuses me.

  4. Kent definitely has talent and he may even "win" the afternoon drive time competition, but do we really need 3 local sports talk shows? Can't we get just one show with a national presence?!? I loved Doug Gottlieb in that slot and have now switched back to music. How many times can we talk about Hibbert's implosion or Reggie Wayne's knee?? All these guys know national sports, but it always seem to pull right back to Indiana sports (x3).

  5. is only popular in Maroon COunty

ADVERTISEMENT